Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity

OBJECTIVES: Nivolumab is used at 3 mg/kg or fixed doses of 240 mg every 2 weeks. There was no dose–response/toxicity relationship of nivolumab. This study evaluated the efficacy of low-dose nivolumab as an alternative to the financial toxicity of standard-dose nivolumab in treatment of non-small cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Shin Hye, Keam, Bhumsuk, Kim, Miso, Kim, Se Hyun, Kim, Yu Jung, Kim, Tae Min, Kim, Dong-Wan, Lee, Jong Seok, Heo, Dae Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069908/
https://www.ncbi.nlm.nih.gov/pubmed/30094065
http://dx.doi.org/10.1136/esmoopen-2018-000332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069908/
https://www.ncbi.nlm.nih.gov/pubmed/30094065
http://dx.doi.org/10.1136/esmoopen-2018-000332

Ejemplares similares